Latest Breaking News On - Hematology annual - Page 1 : comparemela.com

Quadruplet Therapy and Early-Line CAR T-Cell Therapy Approvals Mark Shifting Standards in Multiple Myeloma

Minoo Battiwalla, MD, MS, discusses the impact of earlier-line FDA approvals for CAR T-cell therapies on treatment outcomes in multiple myeloma.

United statesMinoo battiwallaAmerican society of hematology annual meetingSarah cannon research institute in nashvilleScience summitSarah cannon research instituteHematology annual

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesJohn quiselChristina tartagliaVerge scientific communicationsExchange commissionDisc medicine incDevelopment expensesAmerican society of hematology annual meetingChief executive officerBusiness highlightsUpcoming milestonesHeme synthesis modulatorPatient global impressionPediatric disease designationAnti hemojuvelin antibodyHepcidin suppression

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

WALTHAM - Syndax Pharmaceuticals , a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation of positive data from the pivotal.

United statesNeil gallagherSharon klahreSyndax pharmaceuticalsTime oncology review programExchange commissionAmerican society of hematology annual meetingAmerican society of pediatric hematology oncologyEuropean commissionHead of researchPlenary sessionPivotal phaseAcute leukemiaPediatric experienceHematology annualOrphan drug designation

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

– Consistent safety and efficacy profiles across adult and pediatric populations –

United statesSharon klahreNeil gallagherAmerican society of hematology annual meetingSyndax pharmaceuticalsHead of researchExchange commissionEuropean commissionTime oncology review programPrnewswire syndax pharmaceuticalsAmerican society of pediatric hematology oncologySyndax pharmaceuticals incPlenary sessionAcute leukemiaMeeting presentationsAmerican society

Revumenib Earns FDA Priority Review in R/R KMT2Ar Acute Leukemia

Revumenib, a first-in-class Menin inhibitor, was granted priority review from the FDA for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.

United statesMichaela metzgerAmerican society of hematology annual meetingSyndax pharmaceuticalsHematology annual